NCT04840719

RECO in the Endovascular Treatment of Acute Ischemic Stroke

A Prospective ,Multicenter, Registry Study of RECO in the Endovascular Treatment of Acute Ischemic Stroke

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Investigate Reco ® ,the first clot retriever in china as the primary therapyand remedies in the real world.

Detailed description

Endovascular thrombectomy (EVT) is effective and safe for acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) in major clinical trials. Whether the benefit of EVT in randomized trials could be generalized to clinical practice, especially in developing countries, remains unknown. The Registry was established to evaluate the utilization, and subsequent outcomes of EVT treated AIS patients. This study is a multi-center, prospective registry study initiated by researchers, to investigate Reco ® ,the first clot retriever in china as the primary therapyand remedies in the real world.

Conditions

• Intracranial Artery Occlusion With Infarction (Disorder)

Interventions

Type	Name	Description
DEVICE	RECO

Timeline

• Start date: 2020-05-22
• Primary completion: 2021-12-31
• Completion: 2022-07-30
• First posted: 2021-04-12
• Last updated: 2021-04-14

Locations

1 site across 1 country: China